Evgen Pharma Share Discussion Threads

[daniel levi bmd] 07/3/2021 14:22

Fyi

ShareProphets Covid Stocks Suspension Call. 'Click Bait!'. Pitchfork Mobs Stand Down!

Dan
x

[nico115] 07/3/2021 14:17

Could've bought more though !!Octopus who bought Verditek at 8p ? Now 5pOh dear not a great track record and if eis can claim back most of the losses I would say looking at what directors have invested here they aren't too confident in evg prospects Also they have raised a lot more than what was needed so maybe they aren't confident of future trial results ?

[moneymunch] 07/3/2021 13:21

That was his full 8p entitlement commensurate to his modest shareholding...the real wow is Octopus Investments 7.96%...Gl :-)

[nico115] 07/3/2021 13:15

Director buys 300 qd wow Why so small ?

[moneymunch] 07/3/2021 09:19

Evgen's business model is to advance their pipeline towards commercialisation, and now that they're they fully funded for the forseeable, they can "dramatically acclerate" this development. New high quality shareholders such as Octopus, the market leader, must be supremely confident in Evgen's prospects and potential going forwards, and more disclosures this coming week and news from Huw at anytime, makes this a very exciting and very attractive investment. Gla ;-)


Multiple value inflection points, licensing deals in our therapy areas range from $90m to $325m with $11m to $35m upfront and double digit royalties.


Commenting on the Fundraising, Huw Jones, CEO of Evgen Pharma plc, said:

"This heavily oversubscribed fundraising is transformative for us and allows us to accelerate both our future clinical and current pre-clinical work dramatically, together with expanding our senior management team to support our growth. We are very pleased with recent progress of our work on SFX-01 and are most grateful for the support shown in this placing by existing shareholders. The Placing also brings a number of new, high quality shareholders to our register and we offer a warm welcome to them as we accelerate our progress in a range of cancers and acute respiratory distress."

[s_murray] 06/3/2021 19:35

dlg3.

That must be of interest to a big pharma. You would think they would want to be part of something novel like that. Some decent deals been going about recently.

[dlg3] 06/3/2021 19:11

The benefits of Sulforaphane have been know for many years but until Evgen developed stable solid form it was difficult for it to be used in medicine, the benefits of Sulforaphane are endless even prolonging life...the important bit is the production of stable solid for.

[dlg3] 06/3/2021 19:03

Sulforaphane is usually a highly unstable oily liquid, but Evgen has developed a stable, solid form that can be used as an active pharmaceutical ingredient.

[amaretto1] 06/3/2021 12:37

What r u talking about ?There is NO short positions on EVG !

[moneymunch] 06/3/2021 11:54

Well we've got another 40% plus of shareholding disclosures to come, so let's see who else as well as Octopus, holds Evgen's prospects and potential in high regard....this will be bouncing back into double figures soon enough imho... Gl :-)

[on target] 06/3/2021 11:32

The shorting spread-betters are in serious denial about this investment, it just does not fit their narrative at all LOL. It's going to be hilarious to see this play out.

[moneymunch] 06/3/2021 09:32

A solid substantial long term investment by a market leader, very impressive indeed , and maybe missed by most of the market given the timing of Friday's disclosure.....follow the money.....more disclosures to come this week....On and UP!!! Gla ;-)

[moneymunch] 06/3/2021 08:40

Who are the 5 most powerful venture capital funds in Britain?

News

9 Feb 2021

The 5 most powerful venture capital funds in Britain in terms of assets under management are: Octopus Investments, Balderton Capital, Atomico, BGF and Highland Europe.

[moneymunch] 06/3/2021 07:58

A very strong indication on why Jim Mellon and maybe Octopus bought in. Gla :-)


NEWS RELEASE 2-FEB-2021

Aging-US: Sulforaphane promotes C. elegans longevity and healthspan

"The results in this Aging-US research output, indicate that sulforaphane prolongs the lifespan and healthspan of C. elegans through insulin/IGF-1 signaling."

...............

Here, the authors asked whether sulforaphane may influence the lifespan and healthspan of C. elegans.

They found that sulforaphane significantly extends the lifespan of C. elegans and delays age-related phenotype changes.

The analysis of wild-type C. elegans and 9 mutant strains revealed that sulforaphane inhibited DAF-2 insulin/insulin receptor signaling and thereby increased DAF-16 nuclear translocation, resulting in the expression of the sod-3, mtl-1 and gst-4 target genes, which are known mediators of longevity in C. elegans.

The Herr Research Team concluded in their Aging-US Research Paper, "we are the first to report that sulforaphane prolongs the lifespan and increases the healthspan of C. elegans through the inhibition of DAF- 2/insulin/IGF-1 signaling and the activation of DAF- 16/FOXO nuclear transcription in C. elegans. Our study provides a promising hint regarding the suitability of sulforaphane as a new anti-aging drug. However, additional studies in invertebrates and mammalian model organisms are necessary to expand our findings."

[moneymunch] 06/3/2021 07:54

Boom time - Jim Mellon

Longevity science will, I think, lead to the biggest stock market boom ever. It will make the recent medical cannabis boom look like nothing. For the first time in the history of mankind, the elixir of youth, the promise of living a longer life, will actually come true.

There is no one pill that you can take, but a combination of several pharmaceuticals, gene therapies, gene-related technology and treatments could extend your lifespan to 120.

I’m confident in predicting that the science of longevity will represent the biggest industry on the planet within 20 years, and that it will be affordable for everyone after about ten years of commercial exploitation.

Wear and tear

It is important to note that we’re not predestined to die. But as time goes on, the healing process of our body gets overwhelmed – wear and tear overwhelms repair.

We gradually go into a process called ‘loss of homeostasis’, which signals that our inner chemical balance is beginning to get upset, which eventually results in death.

There are some creatures out there, such as the C. elegans worm, which Google’s ageing company Calico is studying, that are made up of atoms and molecules just like us but don’t die naturally. Science has shown that the lifespan of a worm can be increased by up to 20 times using genetic manipulation.

Similar principles can apply to humans. There is a huge amount of bioscience activity in the UK, which is not widely known. There have been negative developments in the form of Neil Woodford’s investments and the government’s lack of funding in this area.

But now people like Sir John Bell are spearheading major efforts to build a home-grown industry. Increasingly, the nexus between VC universities and scientist-entrepreneurs that’s made the US so successful in this field is developing in the UK.

More Juvenescence employees are based here than anywhere else, so we’re very much British. It’s very important to us that the UK retains its status as the second major centre for life sciences in the world.

[moneymunch] 06/3/2021 07:52

Yep, certainly does, and for any newbies looking in for the first time, Jim Mellon is the Chairman of Juvensescene who signed a licensing agreement with Evgen 15/9/20, and so maybe one of the many possible reasons why Octopus have bought 21.8m shares representing 7.96%......Exciting times....Gla ;-)

Details of the Agreement

The license is for exclusive rights to exploit certain patents and know-how for all non-pharmaceutical applications in the United States, with options for the other major markets namely, Europe, Asia and the Rest of the World. Evgen will receive upfront and milestone payments of up to $10.5m, and in addition, royalties on sales. Evgen received an initial payment of $250k on signing of the Agreement.

Barry Clare, Executive Chairman of Evgen, said: "This deal is a strong demonstration of the broad potential for our sulforaphane platform and achieves monetisation in an area which is outside our focus of therapeutic development in the Nrf2 and STAT3 pathways. Juvenescence has a science-driven approach to nutritional health products and brings in-depth experience in this sector. We are delighted to have them as a partner. "

Colin Watts, Chief Executive Officer of JuvLife Division, said : "We are pleased to reach an agreement with Evgen to leverage their scientific technology and expertise to create a differentiated and innovative new product for the global consumer nutritional health market. Juvenescence has built a reputation as a broad-based healthcare company in the Longevity space through strong partnerships with scientific leaders in their specific areas and we are delighted to have such a partner in Evgen."

[awise355] 06/3/2021 07:23

Looks positive to me!

[moneymunch] 05/3/2021 18:43

Octopus Investments Octopus Venutures, all part of the Octopus Group, who now hold 8% of Evgen...I wonder if Jim Mellon has bought in??? Gla ;-)

Biohacking and the future of health and Longevity

February 14, 2020



Talking investment with Octopus Ventures’ Uzma Choudry and what she’s looking for in a breakthrough technology.

Next week, the first Biohacking Congress will be held in London, bringing together famous biohackers, renowned scientists, healthcare professionals, researchers, authors and investors focused on helping us all live a longer and healthier life.

A key component of the event is a start-up competition, which is part of the Startup World Cup, a global competition with a grand prize of $1 million. Seed and Series A level start-ups from MedTech, digital health, biotech and healthcare will pitch to a panel of experts at Biohacking Congress, including Uzma Choudry, PhD, an investor at Octopus Ventures.

With more than £1 billion under management today, Octopus Ventures started out as a generalist Venture Capital (VC) firm, but in recent years has focused on three key pillars of investment: Deep Tech, Future of Money and Future of Health.

Uzma is focused on assessing investment opportunities, conducting preliminary due diligence and executing deals. Her experience straddles the Deep Tech and Future of Health Pods, and she is now focused on Frontier Technologies within health and biotech such as synthetic biology and nanotech, genomics, gene editing and computational biology. This includes platforms at the intersection of technology and biology, including human augmentation and neurotech.

“We’re starting to build more expertise in the frontier technologies within health and seeing a number of life sciences opportunities which fit in that bracket,” she says. “And that’s where we feel there’s an overlap between deep tech and health.”

“… we asked ourselves whether Longevity is a space we should be looking at? … We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box …”

 

In terms of biohacking specifically, Choudry, with a PhD in synthetic biology and biophysics, has a keen personal interest. She points at the opportunity presented by advancements in the genomics space – initially around the ability to read the “biological” software (genome) through more cost-effective DNA sequencing technology, but further now in developments around gene editing tools, such as CRISPR-Cas3/9, which provide the ability to write and edit the software/genes, and opening up a massive opportunity.

........

As far as her views on Longevity as a sector goes, Choudry has spent time with Juvenescence’s Jim Mellon and the people who manage his investment funds.

“There were interesting views on lifespan versus health span, and we asked ourselves whether Longevity is a space we should be looking at?” she says. “We think it is because the areas that we want to look at are those where we think there is a large opportunity or big global challenges that we could be solving. Longevity certainly ticks that box, the aging population is something that is at the front of our mind. Probably more so around health span rather than lifespan – how are these people able to keep good health into their later years. Those are some of the areas that we are looking at within our future of health team.”

[moneymunch] 05/3/2021 18:11

Anyways, I reckon Octopus are very high profile and definitely high quality and will attract interest here, and so looking forward to further disclosures next week...Evgen are gearing UP for growth. Gla :-)

[moneymunch] 05/3/2021 18:07

I'm surprised that you haven't heard yet, who's your account with? My allocation was confirmed yesterday along with c65% additional, and so I'm waiting for a few quid back too from the 35% I didn't get, which can take up to 2 weeks according to the corporate action details, I wasn't expecting the full 100% and was aware that I'd have to wait the refund. Gl :-)

[on target] 05/3/2021 17:59

Sounds like you need to have a word with your broker then fozzie.

[fozzie] 05/3/2021 17:58

MM I am more annoyed that my money is tied up and I don’t even know for sure whether I’ve got them or not.

[moneymunch] 05/3/2021 17:55

Lol...that's the magnetic force of the 8p placing price, although I reckon 8p will be a distant memory imho...more disclosures next week and Huw might plenty of potential positive newsflow from Huw in the coming weeks. Gl :-)

[amaretto1] 05/3/2021 17:51

Ageing process ...Very very interesting ...